A novel single-sided groove target release biodegradable stent inhibits coronary artery intimal hyperplasia
10.3969/j.issn.2095-4344.2017.26.021
- VernacularTitle:新型生物可降解单面刻槽载药靶向支架对冠状动脉内膜增生的影响
- Author:
Hui JIN
;
Meng LI
- From:
Chinese Journal of Tissue Engineering Research
2017;21(26):4222-4227
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND: Theoretically, a novel single-sided groove target release biodegradable stent can avoid drug-induced inflammation of the local vessel wall, reduce drug dose, decrease the likelihood of thrombosis, and relieve stenosis.OBJECTIVE: To evaluate the influence of the novel single-sided groove target release biodegradable stent on intimal hyperplasia in a healthy porcine coronary artery model.METHODS: Eighteen healthy pigs were randomly divided into three groups, bare metal stent group, Firebird metal stent group and Firehawk stent group, which were implanted with L605 cobalt chromium alloy bare metal stents and L605 cobalt chromium alloy non-biodegradable rapamycin-eluting stent and L605 cobalt chromium alloy biodegradable rapamycin-eluting stent, respectively. Two same stents were implanted into the left anterior descending artery and the right coronary artery of each pig, respectively. After 1 and 3 months of follow-up, coronary angiography was performed,and the pigs were killed to take coronary artery samples for detection of intima hyperplasia.RESULTS AND CONCLUSION: At 1 and 3 months after stent implantation, no stenosis, thrombosis and aneurysm occurred in the three groups shown by the coronary angiography; the lumen loss was significantly lower in the Firebird metal stent group and Firehawk stent group than the bare metal stent group (P < 0.05), while there was no difference between the Firebird metal stent group and Firehawk stent group. Histopatologically, there was no coronary arterial tissue necrosis or luminal thrombosis in the three groups. Compared with the bare metal stent group, at 1 and 3 months after stent implantation, the neointimal area and the percentage of stenosis were significantly lower in the Firebird metal stent group and Firehawk stent group (P < 0.05), while the residual lumen area and internal elastic lamina area were significantly higher (P < 0.05). Additionally, there was no significant difference between the Firebird metal stent group and Firehawk stent group. Overall, the Firehawk stent that achieves the same clinical efficacy as the non-biodegradable rapamycin-eluting stent effectively inhibits intimal hyperplasia, and prevents stent restenosis after stent implantation.However, future investigations on the long-term effect are warranted.
